Checkpoint inhibitors in the treatment of urological malignancies

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Checkpoint inhibitors are monoclonal antibodies targeting T-cell or tumor cell receptors like CTLA-4, PD-1, and PD-L1.
• Approved for melanoma, lung, and other cancers since 2010, they represent a significant advancement in cancer therapy.
• Urological cancers, including urothelial and renal-cell carcinomas, are immunogenic, suggesting potential efficacy for immunotherapy.

Purpose of the Study:

• To review the current status and clinical development of checkpoint inhibitors in treating urological tumors.
• To highlight the approved agents and ongoing research in this field.

Main Methods:

• Review of clinical trials and literature on checkpoint inhibitors in urological cancers.
• Analysis of approved drugs and drugs in clinical development phases.

Main Results:

• Two checkpoint inhibitors, atezolizumab and nivolumab, are FDA-approved for metastatic urothelial cancer and metastatic renal-cell carcinoma, respectively.
• Numerous other checkpoint inhibitors are in various stages of clinical development for urological malignancies.

Conclusions:

• Checkpoint inhibitors demonstrate significant promise and are increasingly utilized in the treatment of urological cancers.
• Ongoing research and development are expanding the therapeutic landscape for these immunogenic tumors.